ResearchA Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
ResearchDistinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma
ResearchEculizumab Prophylaxis for Systematic Rechallenging Gemcitabine in Gemcitabine-Induced Thrombotic Microangiopathy: A Case Report
ResearchOpen-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer
ResearchPASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer
ResearchMutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
ResearchBridging the Divide: From Universal Germline Testing Guidance to Real-World Implementation in Pancreatic Cancer Care
ResearchBlockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
ResearchClinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma
ResearchClinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
ResearchAnti-KRAS G12C and Anti-EGFR Rechallenge in Chemotherapy-Refractory G12C-Mutated Colorectal Cancer: A Case Report